Core Viewpoint - The company, Mingyue Lens, has established itself as a leading player in the optical lens market in China, with a strong management team and stable financial performance since its inception in 2002 [1] Group 1: Company Overview - Mingyue Lens has over 20 years of experience in the optical lens field and has consistently led in sales volume in the domestic market [1] - The actual controller holds over 60% of the shares, ensuring clear and concentrated ownership [1] - The lens business is the main source of revenue, with steady growth and continuous optimization of the product structure [1] Group 2: Brand and Innovation Strategy - Since 2018, the company has been advancing a "brand strategy" targeting the mid-to-high-end lens market, forming a product matrix to meet diverse consumer needs [2] - The company maintains a research and development expense ratio of over 3%, achieving self-sufficiency in raw materials and establishing global leading R&D centers [2] - The sales model is diversified, focusing on both direct sales and distribution, with thousands of offline stores and a growing online presence [2] Group 3: Product Development and Market Potential - The company is pursuing a differentiated and high-end development path for its lens products, with a focus on myopia management as a new growth avenue [3] - The company has launched the "Easy Control PRO 2.0" product in 2024, with effective rates for delaying myopia progression at 73.82% and axial growth at 69.3% [3] - A partnership with Xiaomi for AI glasses indicates significant market potential, with early sales exceeding expectations [3] Group 4: Financial Forecast and Investment Outlook - The company is expected to see net profits of 200 million, 220 million, and 260 million yuan in 2025, 2026, and 2027 respectively, driven by brand innovation and product differentiation [4] - The focus on high-potential markets like AI glasses and continuous product upgrades is anticipated to create new growth points for the company [4]

Group 1 - The core viewpoint is that with the increasing health awareness among the public, there is a growing demand for oral management and myopia correction services, as evidenced by a 45% year-on-year increase in search volume for keywords like "teeth correction" and "myopia surgery" since July, and over 60% growth in orders for dental clinics and ophthalmology institutions [2] - Meituan Health has launched the "Worry-Free Purchase" campaign in August, collaborating with over 20,000 dental and ophthalmology institutions to provide benefits for parents with school-age children, including services like vision tests and fluoride treatments [2] - The campaign also features a dedicated knowledge section on children's oral and eye health protection, developed in partnership with well-known brands, aimed at educating parents on comprehensive health service options for their children [2] Group 2 - The National Health Commission has been promoting initiatives for the prevention of myopia and oral health among infants, children, and adolescents, with some cities including dental treatments in medical insurance pilot programs [3] - The adoption of advanced technologies such as femtosecond lasers and digital orthodontics has lowered psychological barriers for consumers, making health services more accessible [3] - Meituan's recent collaboration with leading dental and ophthalmology brands aims to provide affordable and professional health services for young people and their families [3]

Core Viewpoint - The article highlights the increasing concern among parents regarding children's eye health due to excessive use of electronic devices during the summer vacation, emphasizing the importance of preventive measures against myopia and eye injuries [1][2]. Group 1: Myopia Prevention - Experts recommend strict control over children's screen time, suggesting breaks every 15 minutes and limiting total daily usage to no more than 1 hour [1]. - A "green prescription" is proposed, advocating for at least 2 hours of outdoor activities daily to utilize natural light as an effective means to prevent myopia [1][2]. Group 2: Eye Injury Risks - The summer vacation period is identified as a peak time for children's eye injuries, with outdoor activities being a significant contributing factor [1]. - Specific risks include injuries from branches while climbing, accidental impacts during sports, and infections from swimming, which can lead to severe conditions like corneal perforation or eye rupture [1]. Group 3: Expert Recommendations - A three-pronged approach to eye care is suggested: 2 hours of outdoor activity daily, fitting myopic children with orthokeratology lenses to improve control effectiveness by 60%, and biannual eye check-ups for children with parents who have high myopia [2].

高视医疗(02407)发布公告，公司附属公司高视创新科技有限公司(高视创新)的"频域生物测量仪"近日已 获得由江苏省药品监督管理局批准的医疗器械注册证。 2023年国家卫健委发布的《中国眼健康白皮书》指出，中国青少年总体近视率约为53.6%。随着近视群 体的不断扩大，近视防控需求的市场也迅速增加。沙利文发布的《中国眼镜镜片行业研究白皮书》指 出，近年来我国近视防控市场规模不断增长，2022年后开始加速，2023年市场规模已经达到人民币 146.8亿元，同比增长43.2%。生物测量仪是近视防控的关键设备，能够对眼轴长度、角膜曲率、晶体厚 度等进行微米级的精确测量，从而能够在监测青少年近视进展、评估近视防控手段的疗效等方面起到重 要作用，同时也是近视屈光手术术前精准评估必不可少的设备之一。 高视创新本次获批的频域生物测量仪(注册证编号：苏械注准20252161508)，基于新一代频域测量原理 开发，相对于大部分传统基于时域原理的同类生物测量仪产品，频域测量原理具有更高的解析度、更快 的成像速度以及更好的信噪比。设备还采用了创新的双光路设计(专利号：CN118526152A)，在进行眼 部参数测量时能够对患者角膜、 ...

Core Insights - GaoShi Medical's subsidiary GaoShi Innovation Technology has received approval for its "Frequency Domain Biometer" from the Jiangsu Provincial Drug Administration, marking a significant advancement in the company's product offerings [1][2] - The demand for myopia prevention and control is rapidly increasing in China, with the overall myopia rate among youth at approximately 53.6% according to the National Health Commission's "China Eye Health White Paper" [1] - The myopia prevention market in China has seen substantial growth, reaching a market size of RMB 14.68 billion in 2023, representing a year-on-year increase of 43.2% [1] Company Insights - The Frequency Domain Biometer, with registration number SuXieZhuZhun 20252161508, is developed based on a new generation of frequency domain measurement principles, offering higher resolution, faster imaging speed, and better signal-to-noise ratio compared to traditional time-domain products [2] - The device features an innovative dual optical path design, allowing for real-time cross-sectional imaging of the cornea, retina, and choroid during eye parameter measurements, which aids in monitoring myopia progression and screening for complications [2] - GaoShi Innovation has independently developed the device over two years, achieving 100% localization of key optical, mechanical, and electrical components [2]

格隆汇8月4日丨高视医疗(02407.HK)宣布，公司附属公司高视创新科技有限公司("高视创新")的「频域 生物测量仪」近日已获得由江苏省药品监督管理局批准的医疗器械注册证。 高视创新本次获批的频域生物测量仪(注册证编号：苏械注准20252161508)，基於新一代频域测量原理 开发，相对於大部分传统基於时域原理的同类生物测量仪产品，频域测量原理具有更高的解析度、更快 的成像速度以及更好的信噪比。设备还采用了创新的双光路设计(专利号：CN118526152A)，在进行眼 部参数测量时能够对患者角膜、视网膜、脉络膜进行即时断层成像，从而在近视随访的同时辅助医生进 行近视并发症的筛查。该设备由高视创新独立自主研发，历时两年，目前已经实现了光、机、电相关关 键零件的100%国产化。 2023年国家卫健委发布的《中国眼健康白皮书》指出，中国青少年总体近视率约为53.6%。随着近视群 体的不断扩大，近视防控需求的市场也迅速增加。沙利文发布的《中国眼镜镜片行业研究白皮书》指 出，近年来我国近视防控市场规模不断增长，2022年後开始加速，2023年市场规模已经达到人民币 146.8亿元，同比增长43.2%。生物测量仪是近视 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Gaush Meditech Ltd 高視醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股 份 代 號：2407） 自願公告 2023年國家衛健委發佈的《中國眼健康白皮書》指出，中國青少年總體近視率約 為53.6%。隨著近視群體的不斷擴大，近視防控需求的市場也迅速增加。沙利 文發佈的《中國眼鏡鏡片行業研究白皮書》指出，近年來我國近視防控市場規 模不斷增長，2022年後開始加速，2023年市場規模已經達到人民幣146.8億元， 同比增長43.2%。生物測量儀是近視防控的關鍵設備，能夠對眼軸長度、角膜 曲率、晶體厚度等進行微米級的精確測量，從而能夠在監測青少年近視進展、 評估近視防控手段的療效等方面起到重要作用，同時也是近視屈光手術術前 精準評估必不可少的設備之一。 – 1 – 高視創新本次獲批的頻域生物測量儀（註冊證編號：蘇械注准20252161508）， 基 ...

Core Viewpoint - The article highlights the growing concern over the marketing and regulation of eye care devices, particularly reading tables and distant screens, which claim to prevent myopia but lack clear medical certification and standards [1][2][10]. Group 1: Industry Standards and Regulations - Current eye care devices like reading tables and distant screens are primarily classified under 3C certification, which is for consumer electronics, rather than as medical devices [8][9]. - There is a significant absence of national standards for these products, with only industry association standards available, leading to confusion and potential consumer deception [10][14]. - Experts call for the establishment of clear regulations and standards to prevent the commercialization of myopia prevention claims and ensure consumer safety [1][16]. Group 2: Consumer Concerns and Misleading Marketing - Many parents are misled by marketing claims that these devices can prevent myopia, often influenced by endorsements from well-known doctors [2][15]. - Some products falsely present themselves as medical devices by showcasing medical registration certificates, which can confuse consumers regarding their actual classification [8][9]. - The marketing strategies employed by companies often exaggerate the effectiveness of these devices, leading to potential violations of advertising laws [15][17]. Group 3: Market Dynamics and Future Directions - The eye care device market is rapidly evolving, with numerous brands entering the space and introducing new products, but the lack of unified standards hampers quality assurance [11][14]. - The increasing prevalence of myopia among children, with rates reported at 52.7% overall, underscores the urgent need for effective and regulated solutions [16]. - Industry experts advocate for a clear classification of these devices based on their intended use and risk, suggesting that those with medical claims should be regulated as medical devices [17][18].

Core Viewpoint - The AI Fund ICBC Healthcare Stock (000831) reported a profit of 209 million yuan for Q2 2025, with a weighted average profit per fund share of 0.1826 yuan, and a net asset value growth rate of 5.88% during the period [2]. Fund Performance - As of July 18, the fund's net asset value growth rates were 17.16% over three months, 28.87% over six months, 26.93% over one year, and -9.65% over three years, ranking 45/54, 38/54, 41/53, and 26/46 among comparable funds respectively [3]. - The fund's Sharpe ratio over the past three years was -0.0674, ranking 25/46 among comparable funds [9]. - The maximum drawdown over the past three years was 36.8%, with the largest single-quarter drawdown occurring in Q3 2022 at 24.01% [11]. Fund Composition and Strategy - As of June 30, the fund maintained an average stock position of 88.71% over the past three years, slightly above the comparable average of 88.19% [14]. - The top ten holdings of the fund as of Q2 2025 included companies such as Heng Rui Medicine, Kelun Pharmaceutical, and BeiGene, among others [19]. Market Outlook - The fund manager expressed optimism regarding long-term trends in refractive surgery technology, increasing penetration rates for myopia prevention, and growth in dental implants and medical aesthetics [2]. - The medical device sector is expected to face challenges in 2024, but a turning point may occur in the second half of 2025 as companies begin to alleviate inventory pressures [2].

Group 1 - The Ministry of Education held a meeting to promote the development of basic education in border areas, focusing on improving public service quality and establishing "border schools" [1] - The National Primary and Secondary School Smart Education Platform launched anti-drug promotional videos to enhance awareness among youth regarding substance abuse [2] - The Ministry of Education released a Q&A on myopia prevention during summer vacation, emphasizing the importance of outdoor activities for at least 2 hours daily to effectively prevent myopia [3] Group 2 - Beijing's transportation authority has cleared over 800 illegally deployed "parent-child bicycles" as part of a special rectification action, identifying three trading platforms and 19 illegal operators [4] - Xueda Education announced that its shareholder, Zhejiang Taizhou Yelinwan Investment Co., Ltd., pledged 5.6 million shares, accounting for 44.98% of its holdings and 4.60% of the company's total share capital [5] - As of the announcement date, the shareholder has cumulatively pledged 12.42 million shares, representing 99.77% of its total holdings and 10.19% of the company's total share capital [5]